Community-Associated MRSA—Not So Innocent Sibling per Se: A Case Report
Main Article Content
Abstract
Background: Methicillin-resistant S. aureus (MRSA) is a major healthcare burden and is classified as healthcare-associated (HA-MRSA) and community-associated (CA-MRSA). While HA-MRSA is clinically feared, CA-MRSA is often considered less pathogenic. This case report highlights the serious course of illness due to CA-MRSA infection and provides a treatment strategy for the management of such cases.
Case description: A 41-year-old male presented with fever and breathlessness for five days. Upon admission, he was provided empirical treatment for atypical infections and vasopressor support for hypotension. His condition deteriorated, necessitating ventilator support. Although the initial tracheal Bio Fire test indicated MRSA, his clinical manifestations did not match MRSA pneumonia symptoms; however, CA-MRSA was confirmed within 12 h. Skin legions developed within 16 h and progressed gradually from ecchymosis, petechial, and palpable purpura to bullous lesions over 72 h. The antibiotic regimen was modified and optimized with the addition of Clindamycin, Vancomycin, and Meropenem–Colistin. Owing to high IL-6 levels, dual vasopressor support, and acute kidney failure, he was started on early (within 12 h) continuous renal replacement therapy (CRRT) with CytoSorb filter (for 3 days) for cytokine removal. IL-6 levels decreased after two days of CytoSorb use. Subsequently, the patient stabilized with reduced dependence on vasopressor and ventilator assistance.
Discussion: Early diagnosis of CA-MRSA and management with CRRT using CytoSorb may help improve patient outcomes. To our knowledge, this is the first report of clinical management of CA-MRSA with CytoSorb therapy in India that resulted in positive outcomes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Lee AS, de Lencastre H, Garau J, Kluytmans J, Malhotra-Kumar S, et al. (2018) Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers 4: 18033. doi: 10.1038/nrdp.2018.33.
II. Adler A, Temper V, Block CS, Abramson N, Moses AE (2006) Panton-Valentine leukocidin-producing Staphylococcus aureus. Emerg Infect Dis. 12: 1789–1790.
III. Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group, India (2013) Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern. Indian J Med Res 137: 363–369.
IV. Natarajaseenivasan K, Shanmughapriya S, Latha R, Artiflavia GB, Kanagavel M, et al. (2012) Prevalence of community acquired methicillin resistant Staphylococcus aureus (CA-MRSA) in skin and soft tissue infections among cases from Puducherry, India. J Public Health. 20: 593–597. doi: 10.1007/s10389-012-0507-x
V. Malviya A, Tomaret A, Bajpai IS, Mutha A (2023) Phenotypic characterization of methicillin resistant staphylococcus aureus (MRSA) and its susceptibility pattern in a tertiary care institute. International Journal of Scientific Research 12: 2023. doi: 10.36106/ijsr/2603043.
VI. Kutnik P, Borys M (2019) Applications of Cytosorb in clinical practice. J Pre-Clin Clin Res 3: 162–166. doi: 10.26444/JPCCR/112882.
VII. Poli EC, Simoni C, André P, Buclin T, Longchamp D, et al. (2019) Clindamycin clearance during Cytosorb® hemoadsorption: A case report and pharmacokinetic study. Int J Artif Organs 42: 258–262. doi:10.1177/0391398819831303
VIII. van der Linde GW, Grootendorst AF (2016) The first case of toxic shock treated with haemo adsorption by CytoSorb® in the Netherlands. Neth J Crit Care. 24: 27–29.
IX. Scandroglio AM, Pieri M, Nardelli P, Fominskiy E, Calabrò MG, et al. (2021) Impact of CytoSorb on kinetics of vancomycin and bivalirudin in critically ill patients. Artif Organs 45: 1097–1103. doi: 10.1111/aor.13952.
X. Rugg C, Klose R, Hornung R, Innerhofer N, Bachler M, et al. (2020) Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective ‘genetic’ matched analysis. Biomedicines 8: 539. doi: 10.3390/biomedicines8120539.